Alcon Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $10.4B+4.9% YoYTTM through 31 Dec 2025
Net Income $980M-3.7% YoYTTM through 31 Dec 2025
Free Cash Flow $1.7BTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 55.2% |
| EBITDA Margin | 15.5% |
| Operating Margin | 13.1% |
| Net Margin | 9.4% |
Returns
4.4%ROE
3.1%ROA
4.0%ROIC
Balance Sheet Health
Debt / Equity0.19x
Current Ratio2.12x
Net Debt$2.6B
Cash & Equivalents$1.5B
Quality Metrics
Piotroski F-Score6 / 9
FCF Margin16.6%
Rule of 4023.2
Earnings-Beat Rate25.0%
Multi-Year Trend
RevenueFY2025: $10.4B
Diluted EPS$1.98TTMFY2025: $1.99
Dividend
$0.36Per share, FY20260.55%Yield5 yrsStreak+26.6%5-yr growth
Capital Allocation
R&D Spend$990M
Capex Intensity5.2%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Surgical | $5.8B | +4.0% | |
| Vision Care | $4.6B | +6.0% |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.